C
Cellectis
Paris, France
Founded 1999 NASDAQ: CLLS
Nanomedicine Gene Therapy Delivery Cell Therapy Nano Nano-Bio Protein Engineering Regenerative Medicine
About
TALEN gene editing for allogeneic CAR-T cell therapy
Company Details
- Type
- public
- Employees
- 300+
- Funding
- Public
Key Products
- UCART
- TALEN Technology